Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 154.98M P/E - EPS this Y - Ern Qtrly Grth -
Income -26.34M Forward P/E -0.02 EPS next Y - 50D Avg Chg -
Sales 10M PEG - EPS past 5Y - 200D Avg Chg 25.00%
Dividend N/A Price/Book 2.50 EPS next 5Y - 52W High Chg -18.00%
Recommedations 1.50 Quick Ratio 4.57 Shares Outstanding 140.27M 52W Low Chg 151.00%
Insider Own 0.54% ROA -20.59% Shares Float 440.01M Beta -
Inst Own 60.03% ROE -46.10% Shares Shorted/Prior 2.83M/2.33M Price 1.24
Gross Margin 70.79% Profit Margin -263.41% Avg. Volume 1,930,119 Target Price 6.25
Oper. Margin -256.48% Earnings Date Mar 29 Volume 485,900 Change -8.15%
About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Mereo BioPharma Group plc News
05/15/24 Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/12/24 MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
04/03/24 Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
03/27/24 Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results
03/27/24 Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
03/05/24 Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
02/16/24 Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
02/16/24 15 Top Performing European Stocks So Far in 2024
01/08/24 Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
01/08/24 Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
11:21 AM Hedge Funds Say These Penny Stocks Are Poised to Explode
11/03/23 Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
10/23/23 Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
10/14/23 Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
10/09/23 Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
09/21/23 Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
09/07/23 Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
08/10/23 BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC
08/04/23 Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
07/07/23 Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
MREO Chatroom

User Image Mitchell9898 Posted - 1 day ago

$MREO @bull_goes_mooo thoughts now?

User Image Hoekie12 Posted - 1 day ago

$MREO I sold some at 3,15 last week. Luckily it come down again. Bought in at 3,11 😅

User Image BeerBubbelah Posted - 1 day ago

$MREO

User Image Mitchell9898 Posted - 1 day ago

$MREO the whole damn chart is a bull flag lol

User Image bull_goes_mooo Posted - 2 days ago

$MREO Make or break time

User Image halpy518 Posted - 2 days ago

$MREO wtf

User Image astroflyery1 Posted - 2 days ago

$OPTN $XERS $MREO $STRO $HRTX I'm pleased to announce that I achieved break-even. As I said before, the underlying conditions are set for a significant upside movement.

User Image Berakhot Posted - 2 days ago

$MREO

User Image Berakhot Posted - 2 days ago

$RARE $MREO

User Image stately Posted - 2 days ago

$MREO There was a chance of breaking out of this today, but it's looking iffy...

User Image ScottyDoesntKnowMeSon Posted - 2 days ago

$MREO multiple retests on that channel breakout. Closer to a breakout

User Image OutperformGER Posted - 2 days ago

$RARE and $MREO Emil Kakkis is a great CEO 👇

User Image brd03 Posted - 3 days ago

$MREO https://x.com/ej23ny/status/1790891012090401003?s=46

User Image Berakhot Posted - 3 days ago

$MREO "The partnership with Ultragenyx includes potential additional milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories. Setrusumab has received orphan designation for osteogenesis imperfecta from the EMA and FDA, PRIME designation from the EMA and has pediatric disease designation from the FDA. Alvelestat has received U.S. Orphan Drug Designation for the treatment of AATD and Fast Track designation from the FDA." https://www.globenewswire.com/en/news-release/2024/05/15/2882866/0/en/Mereo-BioPharma-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

User Image brd03 Posted - 3 days ago

$MREO https://x.com/wkissel/status/1790857040346403020?s=46

User Image brd03 Posted - 3 days ago

$MREO https://x.com/beerbubbelah/status/1790787466116374814?s=46

User Image astroflyery1 Posted - 3 days ago

$MREO Cash and cash equivalents of $48.7 million as of March 31, 2024. Completed enrollment in Phase 3 Orbit and Cosmic studies for setrusumab in OI. Ongoing pre-launch activities in Europe for setrusumab. Initial validation work for the SGRQ instrument in AATD-LD population completed. 25% decrease in R&D expenses, primarily due to reduced etigilimab costs. 8% reduction in general and administrative expenses. Net loss decreased from $12.1 million in Q1 2023 to $9.0 million in Q1 2024. Mereo expects to fund operations into 2026 with current cash reserves.

User Image DonCorleone77 Posted - 3 days ago

$MREO Mereo BioPharma files to sell $175M of American Depositary Shares

User Image PDM5 Posted - 3 days ago

$MREO "Mereo also announced progress in partnering discussions and research for alvelestat and etigilimab." Something to be hopeful for?

User Image Elvira007 Posted - 3 days ago

$MREO You know, let us release earnings on last possible day for Q1 and NOT DO any conference calls for investors at the greatest time in the company's history because we are arrogant . Who wants to answer questions from fu*king investors. Leave it up to me..... F*ck You Mereo Shareholders. Here is the same update we gave in January.....

User Image Stock_Titan Posted - 3 days ago

$MREO Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/MREO/mereo-bio-pharma-reports-first-quarter-2024-financial-results-and-wpi876drt023.html

User Image Elvira007 Posted - 3 days ago

$MREO Rubric manages a billion dollar portfolio. I would have likely moved on dealing with this team but she must have really got under his skin to go this route. Now , he is sitting on his ass again... Can't even call him an activist anymore... More like pacified shareholder....

User Image Laran900 Posted - 4 days ago

$MREO rubric has no cred when it comes to activist mgmt, hes terrible at this. He should take notes from hestia capital

User Image LDT79 Posted - 4 days ago

$MREO patience, I casted my vote but we can only hope Rubric votes accordingly, it’s their chance to replace the CEO once for all - it’s crystal clear she has no interest in creating shareholder value other than milking her salary + free shares . Enough is enough!

User Image BeerBubbelah Posted - 4 days ago

$MREO Latest 13F’s: Tejara decreased shares by 1.2 mil, Qube increased by 77k, and Veriton bought 485k. Not concerned by Tejara considering they still own almost 2.5 mil. They most likely sold the shares because it was pure profit and to diversify.

User Image brd03 Posted - 5 days ago

@mritwont @BioAmerica $bctx $MREO

User Image Elvira007 Posted - 5 days ago

$MREO Wake the f*ck up you mindless **nts... CEO needs to be fired at this point....Do your fucking job....

User Image OutperformGER Posted - 5 days ago

$MREO @CEOofstocks can you post an actual chart please? Thanks a lot ✌️

User Image BeerBubbelah Posted - 5 days ago

$MREO Just showing a few posts from this sexy bastard on X today. Some nice investments by the tutes

User Image LDT79 Posted - 5 days ago

$MREO perfect time for news

Analyst Ratings
Cantor Fitzgerald Overweight May 16, 24
Needham Buy May 16, 24
Needham Buy Apr 10, 24
Cantor Fitzgerald Overweight Mar 28, 24
Needham Buy Mar 28, 24
Cantor Fitzgerald Overweight Mar 22, 24
Cantor Fitzgerald Overweight Sep 8, 23
Needham Buy Sep 8, 23
Needham Buy Aug 23, 23